MiMedx GroupMDXG -0.39%57 EBITDA Margin % is -22.57% as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, MiMedx Group ranks better than 77.86% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. MiMedx Group's EBITDA for the
three
months ended in Mar. 2026 was $-13.3 Mil. MiMedx Group's Revenue for the
three
months ended in Mar. 2026 was $59.0 Mil. Therefore, MiMedx Group's EBITDA margin for the quarter that ended in Mar. 2026 was -22.57%.
MiMedx Group (NAS:MDXG) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MiMedx Group EBITDA Margin % Related Terms
MiMedx Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for MiMedx Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXG vs ASMB, AGMB, TRAX: EBITDA Margin % Comparison
For the Biotechnology subindustry, MiMedx Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MiMedx Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a EBITDA Margin % of -22.57% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MiMedx Group and its competitors. According to the industry distribution chart, MiMedx Group ranks #209 out of 944 companies in the Biotechnology industry, placing it in the top 22.1%.
Is MiMedx Group's EBITDA Margin % too high?
MiMedx Group's current EBITDA Margin % is -22.57%. Based on the distribution chart, MiMedx Group ranks #209 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's EBITDA Margin % compare to ASMB and AGMB?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #209 out of 944 companies for EBITDA Margin %. This places MiMedx Group in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MiMedx Group and its competitors. MiMedx Group's current EBITDA Margin % is -22.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.96, compared to a current price of $3.82 — trading 45.2% below its estimated fair value. The current EBITDA Margin % is -22.57%. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MiMedx Group (MDXG), the current EBITDA Margin % is -22.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.82 is trading 45.2% below its estimated GF Value™ of $6.96.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
EBITDA Margin %: -22.57%
GF Value™: $6.96 vs. price of $3.82 (45.2% below fair value)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
